Updated:
LYFE Capital
Norbert Hu and Steve Chen founded LYFE Capital in 2010 out of Shanghai, initially as a healthcare-focused private equity firm.
LYFE Capital
Norbert Hu and Steve Chen founded LYFE Capital in 2010 out of Shanghai, initially as a healthcare-focused private equity firm. The firm has since expanded its mandate to include technology, but its core identity remains rooted in healthcare services, biotech, and medtech investing across China. LYFE Capital targets growth-stage and pre-IPO companies, typically deploying $50 million to $100 million per round. Its portfolio includes investments in Chinese healthcare platforms like iKang Healthcare (which it helped take private in 2016), biotech firm BeiGene, and digital health company WeDoctor. The firm also backs enterprise software and consumer tech. Its geographic focus is primarily China, with selective exposure to other Asian markets and the United States. The firm does not publicly disclose AUM or team size. It maintains a single Shanghai office and operates with a lean investment team. LYFE Capital has not launched a reported fund vehicle since its predecessor structures; it appears to invest through discretionary mandates or co-investment SPVs. There is no known recent public activity in the last 24 months. LYFE Capital's structural differentiator is its narrow sector focus within healthcare — it concentrates nearly all capital on healthcare delivery, biopharma, and medical devices, a level of specialization rare among growth-stage private equity firms in China. This specialization shapes sourcing, underwriting, and post-investment support.
General information
Firm type
Asset Manager
Year founded
2010
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Principals
Norbert Hu
Founder & Managing Partner
Steve Chen
Co-Founder & Managing Partner
Sector focus
Frequently asked questions
Who runs investment decisions at LYFE Capital?
Investment decisions at LYFE Capital are led by co-founders Norbert Hu and Steve Chen. Hu focuses on healthcare and biotech opportunities while Chen oversees technology investments. The firm operates with a small generalist team, though specific committee structures are not public (per public record).
How does LYFE Capital source proprietary deal flow?
LYFE Capital sources deal flow through its network of relationships within China's healthcare and technology ecosystems. The firm's specialization in healthcare gives it credibility with founders in that sector. It also co-invests alongside other Asian and US-based growth equity firms, which generates inbound referrals.
Is LYFE Capital structured as a single family office or does it operate more like a venture firm?
LYFE Capital operates as a traditional private equity and venture capital firm, not a family office. Its legal structure is an asset management company registered in Shanghai. The firm does not disclose whether a single family provides its capital base.
What investment stages does LYFE Capital typically target?
LYFE Capital focuses on growth-stage and pre-IPO investments. Typical check sizes range from $50 million to $100 million per round. The firm has also participated in public direct investments, such as its stake in iKang Healthcare, which it helped take private.
Which sectors does LYFE Capital explicitly avoid?
LYFE Capital does not publicly list any sectors it avoids. Given its stated focus on healthcare and enterprise software, it likely steers clear of heavy industry, commodities, real estate, and consumer discretionary sectors.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: